Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
SUNNIFORECAST (Sunitinib vs. Nivolumab + Ipilimumab as First line treatment Of REnal cell
CAncer of non-clear cell SubTypes) is a Phase II, randomized, open-label investigator
initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care
in subjects with previously untreated and advanced (unresectable or metastatic) non-clear
cell renal cell carcinoma (nccRCC).